Bruce Strober MD PhD

PubMed

• Systemic Corticosteroid Use in Atopic Dermatitis: A Position Paper to Inform Safer Clinical Practice and Policy.
  Joshua Burshtein, Christopher G Bunick, Ruth Ann Vleugels, April W Armstrong, Alexandra K Golant
  The Journal of Investigative Dermatology. 2025-09-06
• Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares.
  James G Krueger, Mrinal K Sarkar, Mark G Lebwohl, Akimichi Morita, Kenneth Gordon
  The Journal of Clinical Investigation. 2025-09-02
• Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-l...
  Andrew Blauvelt, Richard G Langley, Mark Lebwohl, Bruce Strober, Richard B Warren
  Journal of the American Academy of Dermatology. 2025-09-01

Journal Articles

• Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis  
  Tan H, Gupta P, Harness J, Wolk R, Chapel S, Menter A, Strober B, Langley RG, Krishnaswami S, Papp KA, CPT: Pharmacomet Syst Pharmacol, 1/1/2013

Books/Book Chapters

• Fitzpatrick's Dermatology in General Medicine 
  Chapter: Chapter 220: "Topical and Intralesional Cytotoxic Agents" 
  Moore MM and Strober BEEditors: K. Wolff, et al..McGraw-Hill Companies, Inc., USAEdition 7th,2008
• Fitzpatrick's Dermatology in General Medicine 
  Chapter: Chapter 214: "Principles of Topical Therapy" 
  Bergstrom KG, Strober BEEditors: K. Wolff, et al..McGraw-Hill Companies, Inc., USAEdition 7th,2008
• Psoriasis and Psoriatic Arthritis: An Integrated Approach 
  Chapter: Chapter XA2: "TNF Antagonist Therapy" 
  Strober BEEditors: K.B. Gordon and E.M. Ruderman.Springer Berlin Heidelberg, New York2005
• Seminars in Cutaneous Medicine and Surgery 
  Chapter: Chapter 24: "The Treatment of Psoriasis with Etanercept" 
  Page 28 - 36Strober BEEditors: J. Sobell.W.B. Saunders Co., Ltd.Edition 1st,2005
• Fitzpatrick's Dermatology in General Medicine 
  Chapter: Chapter 242: "Principles of Topical Therapy" 
  Page 2578 - 2584Strober BE, Washenik K, Shupack JLEditors: IM Freedberg, et al..McGraw Hill, USAEdition 6th,2003
• Current Dermatologic Diagnosis and Treatment 
  Chapter: Arthropod Bites 
  Strober BE, Day DJEditors: IM Freedberg and MR Sanchez.Lippincott Williams & Wilkins, Philadelphia2001
• Current Dermatologic Diagnosis and Treatment 
  Chapter: Granulomatous Processes 
  Strober BE, Stern RLEditors: IM Freedberg and MR Sanchez.Lippincott Williams & Wilkins, Philadelphia2001
• Current Dermatologic Diagnosis and Treatment 
  Chapter: Hypertrichosis and Hirsutism 
  Strober BE, Nanni CNEditors: IM Freedberg and MR Sanchez.Lippincott Williams & Wilkins, Philadelphia2001
• Join now to see all

Abstracts/Posters

• Psoriasis Patients with PASI90 Response Achieve Greater Health-related Quality of Life Improvements than Those with PASI75 Response
  McLeod L, Mallya U, Fox T, Strober B, 23rd Congress of the EADV, Amsterdam, The Netherlands, 1/1/2014
• Phase 2 Study of Brodalumab (AMG827) For Moderate-to-severe Plaque Psoriasis: Week 12 Results on Efficacy and Safety in Patients with Psoriatic Arthritis
  Papp KA, Menter A, Ortonne J-P, Strober B, Kricorian G, Thompson EH, Milmont CE, Nirula A, Klekotka P, CDA 89th Annual Conference, Toronto, Ontario, Canada, 1/1/2014
• Psoriasis Longitudinal Assessment and Registry (PSOLAR): Global Update of a Multicentre, Open Registry of Psoriasis Patients
  Papp K, Augustin M, Ho V, Leonardi C, Menter A, Strober B, Calabro S, Langholff W, Fakharzadeh S, Chevrier M, CDA 89th Annual Conference, Toronto, Ontario, Canada, 1/1/2014
• Improvement of Psoriasis in Subjects with and without Psoriatic Arthritis: Subanalysis of a Brodalumab (AMG 827) Phase 2 Study for Moderate to Severe Plaque Psoriasis
  Papp K, Menter A, Strober B, Kricorian G, Thompson EHZ, Milmont CE, Nirula A, Klekotka P, AAD 72nd Annual Meeting, Denver, Colorado, 1/1/2014
• Psoriasis Longitudinal Assessment and Registry (PSOLAR): Global Update of a Multicentre, Open Registry of Psoriasis Patients
  Strober B, Menter A, Leonardi C, Chevrier M, AAD 72nd Annual Meeting, Denver, Colorado, 1/1/2014
• Secukinumab Impact on Patient-reported Psoriasis Symptoms of Pain, Itching, and Scaling Compared to Placebo and Etanercept (FIXTURE Study).
  Strober B, Gottlieb A, Notter M, Tran MH, AAD 72nd Annual Meeting, Denver, Colorado, 1/1/2014
• Psoriasis Longitudinal Assessment and Registry: Global Update upon Full Enrollment
  Strober B, Menter A, Leonardi C, Goyal K, Langholff W, Calabro S, Fakharzadeh S, 23rd Congress of the EADV, Amsterdam, The Netherlands, 1/1/2014
• Safety of Ustekinumab from the Placebo-controlled Periods of Psoriatic Arthritis and Psoriasis Clinical Developmental Programs
  McInnes I, Papp K, Puig L, Reich K, Ritchlin C, Strober B, Rahman P, Kavanaugh A, Mendelsohn A, Song M, Chan D, Shen YK, Li S, Gottlieb AB, EULAR Annual European Congress of Rheumatology, Madrid, Spain, 1/1/2013
• The Effects of Adalimumab on C-reactive Protein and Sleep in Moderate to Severe Psoriasis Patients with Suboptimal Response to Etanercept, Methotrexate, or Phototherap...
  Strober B, Goldblum O, Wang Y, Poulin Y, 71st Annual Meeting of the AAD, Miami, Florida, 1/1/2013
• Secukinumab Reduces C-reactive Protein Levels in Patients with Moderate to Severe Plaque Psoriasis: Result of a Regimen-finding Study
  Strober B, Guettner A, Sigurgeirrson B, Papavassilis C, 71st Annual Meeting of the AAD, Miami, Florida, 1/1/2013
• PSOLAR: Global Update of a Multicenter, Open Registry of Psoriasis Patients
  Papp K, Strober B, Chevrier M, Ho V, 71st Annual Meeting of the AAD, Miami, Florida, 1/1/2013
• Malignancy Events in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Study: Current Status of Observations
  Langley R, Strober B, Chevrier M, Lebwohl M, 71st Annual Meeting of the AAD, Miami, Florida, 1/1/2013
• Infections in the Ustekinumab Psoriasis Clinical Trial Program: Final Report with up to 5 Years of Follow-up
  Strober B, Lebwohl M, Ghislain PD, Szapary P, 71st Annual Meeting of the AAD, Miami, Florida, 1/1/2013
• Long-term Safety of Ustekinumab: 5 Years of Follow-up from the Psoriasis Clinical Development Program including Patients with Psoriatic Arthritis
  Papp K, Griffiths C, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Shen YK, Ho V, Ghislain PD, Strober B, Reich K, EULAR Annual European Congress of Rheumatology, Madrid, Spain, 1/1/2013
• Malignancy Events in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Study: Current Status of Observations
  Langley R, Strober B, Lebwohl M, Chevrier M, CDA 88th Annual Conference, Quebec City, Quebec, Canada, 1/1/2013
• PSOLAR: Global Update of a Multicentre, Open Registry of Psoriasis Patients
  Papp K, Augustin M, Strober B, Ho V, Fakharzadeh S, Calabro S, Langholff W, Chevrier M, on behalf of the PSOLAR Steering Committee, 4th Congress of the Psoriasis International Network, Paris, France, 1/1/2013
• Brodalumab (AMG 827) Phase 2 Study for Moderate to Severe Plaque Psoriasis: Subanalysis of Efficacy and Safety in Subjects with Psoriatic Arthritis
  Papp K, Menter A, Ortonne J-P, Strober B, Kricorian G, Thompson E, Milmont C, Nirula A, Klekotka P, 22nd Congress of the EADV, Istanbul, Turkey, 1/1/2013
• PSOLAR: Global Update of a Multicenter, Open Registry of Psoriasis Patients
  Papp K, Strober B, Ho V, Binder C, Calabro S, Langholff W, Chevrier M, CDA 87th Annual Conference, Ottawa, Ontario, Canada, 1/1/2012
• Adding Methotrexate to Etanercept versus Etanercept Monotherapy in Adults with Moderate to Severe Plaque Psoriasis: Efficacy and Safety
  Gottlieb AB, Langley RG, Strober BE, Papp K, Klekotka P, Creamer K, Thompson EHZ, Hooper M, Kricorian G, AAD 70th Annual Meeting, San Diego, California, 1/1/2012
• PSOLAR (Psoriasis Longitudinal Assessment and Registry): Update of a Multicenter Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy including ...
  Strober B, Papp K et al., AAD 70th Annual Meeting, San Diego, California, 1/1/2012
• Interim Results from an Open-label Extension Study of Briakinumab for the Treatment of Moderate to Severe Psoriasis
  Langley RG, Papp K, Gottlieb AB, Krueger GG, Strober B, Williams DA, Heckaman MO, Valdes J, Gordon K, AAD 70th Annual Meeting, San Diego, California, 1/1/2012
• Patient-reported Outcomes from a Randomized, Placebo-controlled Study of Etanercept or Etanercept plus Methotrexate in Patients with Moderate to Severe Plaque Psoriasis
  Strober B, Gottlieb A, Langley R, Papp K, Klekotka P, Hooper M, Creamer K, Thompson EH, Gandra SR, Watson C, Kricorian G, CDA 87th Annual Conference, Ottawa, Ontario, Canada, 1/1/2012
• Malignancy Rates in the Ustekinumab Psoriasis Clinical Trial Program: Update with up to 4 Years of Follow-up and Comparisons to the General United States Population
  Papp K, Gordon K, Yeilding N, Szapary PO, Li S, Krueger G, Strober B, Prinz JC, CDA 87th Annual Conference, Ottawa, Ontario, Canada, 1/1/2012
• Content Validity of a Novel Patient-reported Psoriasis Symptom Diary for Patients with Moderate-to-severe Plaque Psoriasis
  Lebwohl M, Nyirady J, Gwaltney CJ, Strober BE, 3rd World Psoriasis & Psoriatic Arthritis Conference 2012, Stockholm, Sweden, 1/1/2012
• Malignancy Events in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Study: Current Status of Observations
  Langley R, Strober B, Lebwohl M, Ho V, Fiorentino D, Fakharzadeh S, Calabro S, Langholff W, Chevrier M, 21st Congress of the EADV, Prague, Czech Republic, 1/1/2012
• Join now to see all

Lectures

• Hand and Foot Psoriasis, Dermatitis, and Other Inflammatory Dermatoses 
  American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/4/2019
• Biologics Psoriasis Guidelines: Translating Evidence into Practice 
  Chicago, Illinois - 1/1/2014
• Use of Biologics in Hidradenitis Suppurativa 
  Naples, Florida - 1/1/2014
• Case-based Discussion on Difficult-to-treat Psoriasis 
  Naples, Florida - 1/1/2014
• Emerging Biologic Therapies for Psoriasis 
  Naples, Florida - 1/1/2014
• Psoriasis Co-morbidities and Prevention of Risk Factors 
  Denver, Colorado - 1/1/2014
• Management of Hand and Foot Psoriasis 
  Denver, Colorado - 1/1/2014
• Relationship between Level of Clinical Improvement and Treatment Emergent and Serious Adverse Events: Results from a Placebo-controlled Phase 2 Clinical Trial of Ixeki... 
  Amsterdam, The Netherlands - 1/1/2014
• Secukinumab's Time to Psoriasis Response on Patient-reported Psoriasis Symptoms (ERASURE Study). 
  Denver, Colorado - 1/1/2014
• Biologic Therapy and Malignancy Risk 
  Denver, Colorado - 1/1/2014
• The Pregnant Pause: How to Evaluate and Treat Your Pregnant Patients 
  Denver, Colorado - 1/1/2014
• Emerging Therapies for Psoriasis 
  Denver, Colorado - 1/1/2014
• New Therapies for Psoriasis and Monitoring of Biologics 
  Miami, Florida - 1/1/2013
• Psoriasis Longitudinal Assessment and Registry (PSOLAR): Global Update of a Multicentre, Open Registry of Psoriasis Patients 
  Istanbul, Turkey - 1/1/2013
• Safety Management of Biologic Agents for Psoriasis 
  Boston, Massachusetts - 1/1/2012
• TNF Inhibitors 
  San Diego, California - 1/1/2012
• Comorbidities in Psoriasis: Cardiovascular Risks and Beyond 
  San Diego, California - 1/1/2012
• Biologics Therapy with Case: Translating Evidence into Practice 
  Boston, Massachusetts - 1/1/2012
• Efficacy and Safety of Briakinumab for Treatment of Moderate to Severe Psoriasis in Patients Previously Receiving Etanercept - Results from an Open-label Extension 
  Lisbon, Portugal - 1/1/2011
• Immunogenicity of Biologic Therapy 
  New Orleans, Louisiana - 1/1/2011
• Emerging Therapies in Psoriasis 
  New Orleans, Louisiana - 1/1/2011
• The Effect of Tasocitinib (CP-690,550), a Novel Oral Janus Kinase Inhibitor, on Patient-reported Symptoms of Pain and Discomfort Associated with Psoriasis, and Patient... 
  Seoul, Korea - 1/1/2011
• Psoriasis Guidelines: Implementing Them in Your Practice 
  New York, New York - 1/1/2011
• The Influence of Body Weight on the Efficacy of Tasocitinib (CP-690,550) In Patients with Plaque Psoriasis 
  Seoul, Korea - 1/1/2011
• Long-term Safety and Efficacy of Briakinumab for the Treatment of Moderate to Severe Psoriasis - Interim Analysis from an Open-label Extension Study 
  New Orleans, Louisiana - 1/1/2011
• Join now to see all

Other

• Core Outcome Sets for Psoriasis Clinical Trials 
  Bruce Strober, MD, JAMA
  https://www.doximity.com/articles/8cc1a023-7261-4aa3-a153-dfbe3310e004
  UpToDate, Wolters Kluwer Health - 2013-02-20